引言近年来，肝内胆管癌(iCCA)的精准靶向治疗取得突破性进展，异柠檬酸脱氢酶-1（IDH1）突变作为可靶向治疗的核心驱动靶点备受瞩目。本期特邀复旦大学附属肿瘤医院赵一鸣教授结合近期新发布的四篇文献，解析东西方IDH1突变率差异原因以及单次活检基因检 ...

张学癌症本质上是一类基因病。首先，要理解“遗传学”这个词的由来。1905年，英国剑桥大学的威廉·贝特森（William ...

日前，美国盖伦基金会（The Galien Foundation）公布了素有“医药界诺贝尔奖”之称的2026年盖伦奖（Prix Galien USA ...

/美通社/ -- LUNGevity基金会宣布六项研究奖的获奖者，这些奖项旨在加强肺癌研究人才队伍，并加速改善肺癌患者的生活。该奖项体现了LUNGevity在推动创新研究和改善患者预后方面的持续承诺。

导读近年来，骨髓增殖性肿瘤（MPN）诊疗的精细化程度持续提升，骨髓纤维化前期（pre-MF）的早期识别与规范化管理已成为血液领域的关注重点。随着新型JAK抑制剂的陆续上市，吉卡昔替尼凭借其在改善贫血、减少血细胞影响等方面的潜在优势，为pre-MF的早 ...

CRISPR-engineered cervical cancer cells carrying the PIK3CA-E545K mutation show coordinated immune signaling and metabolic ...

New Jersey-based mother Lauren Spiezia, 33, completed the grueling race topless to raise awareness for breast cancer after ...

Laboratoires Pierre Fabre announces the approval of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for ...

PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today ...

October and Breast Cancer Awareness Month 2026 may have passed, but this topic is still an issue that impacts the lives of ...

Laboratoires Pierre Fabre Singapore is delighted to announce the access for patients to BRAFTOVI® (encorafenib) in ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced th ...